Mike joined Trevena as Head of Research in February 2008. Prior to this, Mike was Vice President of Biology at Centocor R&D where he was responsible for the therapeutic discovery strategy and execution in immunology, oncology, tissue remodeling and biomarkers. In this role, Mike managed a portfolio of approximately fifteen drug discovery projects as well as supported the development of fourteen new molecular entities (two in late stage clinical development) and one product. Mike was previously Director of Musculoskeletal Diseases at GlaxoSmithKline, where he managed a portfolio of drug discovery projects targeting osteoporosis, osteoarthritis, rheumatoid arthritis and psoriasis. Before joining SmithKline Beecham in 1996, Mike was a Senior Investigator at Merck Research laboratories, where he led a drug discovery team targeting matrix metalloproteinase-3 for the treatment of osteoarthritis. Mike received his BS in Microbiology from thePennsylvania State University and his PhD in Molecular Biology and Microbiology from the Case Western Reserve University Medical School. He completed a postdoctoral fellowship in the Department of Pathology at The University of Washington.
